China’s Next-Generation Antiplatelet Drug CG-0255 Shows Clinical Progress

DengYueMed, a global pharmaceutical service platform closely tracking innovative drug development, notes that cardiovascular therapeutics continue to evolve rapidly, with next-generation antiplatelet agents emerging as a key focus area.

According to publicly available information, as of March 2026, CG-0255 benzenesulfonate capsules remain under clinical development and have not yet been approved in China or globally.

The drug is developed by Shanghai Kejun Pharmaceutical Technology and represents a novel antiplatelet therapy targeting cardiovascular and cerebrovascular diseases.

👉 For more global pipeline insights:
Explore innovative drug updates

---

I. Clinical Development Progress

According to the Center for Drug Evaluation (CDE):

• IND application accepted: January 2025
• Phase I clinical dosing completed: March 2025
• Early results:
  • Favorable safety profile
  • Key endpoints met expectations

Currently:

• 🇨🇳 China: Phase I
• 🌍 Global: Some programs reportedly advancing to Phase III

---

II. A Novel P2Y12 Receptor Antagonist

CG-0255 is a next-generation P2Y12 receptor inhibitor, a critical drug class in preventing arterial thrombosis.

Dual Formulation Strategy

• Intravenous injection
• Oral capsules

This enables broader use across clinical scenarios:

• Acute coronary syndrome (ACS)
• Myocardial infarction
• Ischemic stroke
• Peripheral arterial disease

Potential Advantages

• Rapid onset of action
• Favorable safety profile
• Reduced inter-patient variability
• Lower risk of drug–drug interactions

If confirmed, CG-0255 may become a competitive next-gen alternative in the P2Y12 class.

---

III. Global Demand for Antiplatelet Therapy

Cardiovascular disease remains a leading global cause of death.

Key facts:

• Coronary artery disease (CAD) is one of the most prevalent conditions
• Millions of deaths annually linked to thrombotic events
• Platelet aggregation = core driver of arterial thrombosis

Despite existing therapies, challenges remain:

• Bleeding risk
• Variable patient response
• Drug interactions

👉 These unmet needs are driving innovation in
global cardiovascular drug development

---

IV. China’s Growing Role in Innovation

China’s biopharmaceutical sector is rapidly advancing:

• Increased R&D investment
• Expansion into global clinical trials
• Focus on cardiovascular, oncology, antiviral fields

CG-0255 reflects this broader trend: 👉 From generic manufacturing → to innovative drug development

Although still early-stage, it represents a potential future option in antiplatelet therapy.

---

V. Final Thoughts

The development of CG-0255 highlights a key shift:

👉 Cardiovascular therapy is moving toward safer, faster-acting, and more predictable antiplatelet drugs

As clinical trials progress:

• Safety validation
• Efficacy confirmation
• Global regulatory advancement

will determine its ultimate position in the market.

DengYueMed will continue to track CG-0255 and other innovative therapies:

👉 Follow DengYueMed for latest updates

Providing timely insights into the evolving global pharmaceutical landscape.